Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Susan M. Morand
Observed names:
Morand S,
Morand, Susan,
S. Morand,
Susan M Morand,
Susan Morand
Institutions:
St. Louis Children's Hospital,
Washington University in St. Louis
Observed institutions:
University of Toledo Medical Center,
St. Louis Children's Hospital,
Washington University in St. Louis,
Gradalis (United States),
ProMedica,
University of Toledo
show all 6
ORCID:
0000-0001-9594-0094
Observed ORCID:
0000-0001-9594-0094
OpenAlex ID:
A5036629129
Ovarian Cancer Immunotherapy and Personalized Medicine
2021
·
Susan Morand
, Monika Devanaboyina
, et al.
·
International Journal of Molecular Sciences
·
403
PDF
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials
2020
·
Khalil Choucair
, Susan Morand
, et al.
·
Cancer Gene Therapy
·
188
NF-κB Signaling in Tumor Pathways Focusing on Breast and Ovarian Cancer
2022
·
Monika Devanaboyina
, Jasskiran Kaur
, et al.
·
Oncology Reviews
·
93
PDF
Current Ovarian Cancer Maintenance Strategies and Promising New Developments
2020
·
Vinaya Gogineni
, Susan Morand
, et al.
·
Journal of Cancer
·
79
PDF
Molecular mechanisms underlying rheumatoid arthritis and cancer development and treatment
2020
·
Susan Morand
, Hannah Staats
, et al.
·
Future Oncology
·
41
BRCA1/2 Signaling and Homologous Recombination Deficiency in Breast and Ovarian Cancer
2021
·
Rachel Royfman
, Emma Whiteley
, et al.
·
Future Oncology
·
19
BRCA1/2 Mutation Status Impact on Autophagy and Immune Response: Unheralded Target
2020
·
Susan Morand
, Laura Stanbery
, et al.
·
JNCI Cancer Spectrum
·
17
PDF
Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer
2024
·
Morgan Bailey
, Susan Morand
, et al.
·
International Journal of Molecular Sciences
·
7
PDF
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
2021
·
Elyssa Sliheet
, Molly Robinson
, et al.
·
Cancer Gene Therapy
·
6
PDF
Targeted Molecular Therapy in Palliative Cancer Management
2020
·
Staats H
, Cassidy C
, et al.
·
Insights in Biomedicine
·
4
PDF
NF1 in Solid Tumors: The Unknown Soldier of Tumor Suppressor Genes?
2019
·
Leslie L Lin
, Khalil Choucair
, et al.
·
Genetics & Molecular Medicine
·
4
Clinical characterization and therapeutic targeting of fusion genes in oncology
2025
·
Susan Morand
, Lauren Rager
, et al.
·
Future Oncology
·
2
Relationship of Hypothyroidism and Immune Response to Pegylated IL-10/nivolumab
2020
·
Mary Albrethsen
, Justin Creeden
, et al.
·
Immunotherapy
·
2
Acquired Immunodeficiency in Newborn Following Intrauterine Exposure to Thiopurines for Treatment of Inflammatory Bowel Disease
2026
·
Susan Morand
, Michael T. Lam
, et al.
·
ACG Case Reports Journal
·
1
Signaling pathways in pancreatic ductile adenocarcinoma and potential therapeutic targets
2023
·
Michael A. McHugh
, Nealie T. Ngo
, et al.
·
International Journal of Molecular and Immuno Oncology
·
1
PDF
TROP2-directed antibody-drug conjugates (ADCs) challenge of predicting clinical outcome
2026
·
Laura Stanbery
, Daniel Craig
, et al.
·
Expert Review of Anticancer Therapy
PDF
Potential therapeutic molecular targets for better outcomes for patients with lung cancer
2023
·
Sean T. Mack
, Susan M. Morand
, et al.
·
International Journal of Molecular and Immuno Oncology
PDF
Combination of PARPi and anti-PD-L1 therapies in ovarian cancer
2023
·
Susan M. Morand
, Nealie T. Ngo
, et al.
·
International Journal of Molecular and Immuno Oncology
PDF
117P Tumour mutation burden and response to immune checkpoint inhibitors in solid tumors: A systematic review and meta-analysis
2020
·
K. Choucair
, H. Okut
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
20
Citation count:
867
H-index:
7
I10-index:
7
Year
Topic
Type
